You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

236 Results
Document
Oct 2019
Blog post
Dr. Edward Kucharski Among the many healthcare challenges facing trans and non-binary people, cancer poses a multi-edge threat. Not only are trans...
Nov 2019
Document
Mar 2020
Guidelines and Advice
Status: Current
ID: GL 2-30a
Version: N/A
Mar 2020
 
Document
Sep 2020
Guidelines and Advice
Status: Current
Apr 2021
Statistical Reports
Document
Jan 2021
Regimen
Cancer Type:
Gastrointestinal, 
Gastrointestinal Stromal Tumours
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    ripretinib - For adult patients with advanced gastrointestinal stromal tumours (GIST) who have progression on or intolerance to imatinib, sunitinib and regorafenib
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
ripretinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2025

Pages